Success Payments. Amgen shall pay Infinity success payments for achievements attained by Amgen, its Affiliates or its Sublicensees, in the course of or in relation to a Drug Discovery Program, with respect to Library Compounds or Program Compounds, as follows:
Success Payments. The following payments shall be made in cash (unless otherwise specified below) by Licensee to TSRI within [***] days of the occurrence of any of the following events: Event Payment [***] [***] [***] [***] [***] [***]
Success Payments. (a) If Anadys satisfies the Success Criteria for a Daiichi Target in accordance with Section 1(d), then Daiichi will pay to Anadys a Success Payment of [...***...] United States Dollars (US $[...***...]) for each such Daiichi Target, payable within twenty one (21) days from the date of achieving the Success Criteria. If Daiichi pays one or both Success Payments provided for in this Section 4.2, such Success Payment(s) shall be creditable against ***CONFIDENTIAL TREATMENT REQUESTED
Success Payments. (a) The Company will notify FHCRC within twenty (20) calendar days of the occurrence of any Valuation Date during the Success Payment Period. On each Valuation Date during the Success Payment Period, the Fair Market Value with respect to each share of Series A Preferred Stock shall be determined as of such Valuation Date. If the Multiple of Initial Equity as determined with respect to such Valuation Date is equal to or exceeds any of the values of the Multiple of Initial Equity set forth in Exhibit C attached hereto (the “Trigger Values”), the Company shall be obligated to pay to FHCRC a Success Payment. Such Success Payment shall be due and payable on the Success Payment Date with respect to such Success Payment, in cash or cash equivalents or, in the Company’s (or any successor entity’s) sole discretion, in publicly tradable shares of the Company’s (or such successor entity’s) common stock.
Success Payments. (a) The Company will notify MSKCC within twenty (20) calendar days of the occurrence of any Valuation Date during the Success Payment Period. On each Valuation Date during the Success Payment Period, the Fair Market Value with respect to each share of Series A Preferred Stock shall be determined as of such Valuation Date. If the Multiple of Initial Equity as determined with respect to such Valuation Date is equal to or exceeds any of the values of the Multiple of Initial Equity set forth in Exhibit G attached hereto (the “Trigger Values”), the Company shall be obligated to pay to MSKCC a Success Payment. Such Success Payment shall be due and payable on the Success Payment Date with respect to such Success Payment, in cash or cash equivalents or, in the Company’s (or any successor entity’s) sole discretion, in publicly tradable shares of the Company’s (or such successor entity’s) common stock. The Company recognizes and agrees that MSKCC’s right to the Success Payments hereunder, and the Company’s obligation to pay them, is not dependent upon (i) MSKCC’s ownership of any shares of stock in the Company, whether common or preferred, or (ii) the Collaboration Agreements being in full force in effect, except as set forth in Section 6.
Success Payments. For each Screening Target, Tularik shall pay NeoGenesis a success payment of [*] if at least one Designated Screening Compound is identified by Tularik that shows activity against such Screening Target such that Tularik initiates a Medicinal Chemistry Effort with respect to such Designated Screening Compound. Such payment shall be made within [*] after the initiation of a Medicinal Chemistry Effort by Tularik; PROVIDED, that Tularik has [*] after the date Tularik identifies the Designated Screening Compound for such Screening Target to determine whether or not to initiate a Medicinal Chemistry Effort for such Designated Screening Compound. No payment shall be due NeoGenesis under this Section 4.3 with respect to Shared Targets.
Success Payments. The Commonwealth will pay Success Payments to the SFMA Deposit Account. Upon receipt SFMA will distribute Success Payments to the Funding Partners and SFI in accordance with the Private Funding Agreements. The estimated timing of such Success Payments are detailed in Schedule B (Project Timeline). The maximum Success Payments are $15,000,000.
Success Payments. The Company shall pay you:
Success Payments. Following receipt of the first Regulatory Approval of the Product (either alone or in combination with another drug) (the “Success Payment Trigger”), Opthea will pay Investor the amounts set forth in the “Fixed Success Payment Schedule” below (in the column entitled “Amount of Payment”) on the dates set forth in the column entitled “Date of Payment” (the payments payable pursuant to this Section 6.1.1, the “Fixed Success Payments” and collectively with the Variable Success Payments, the “Success Payments”). Fixed Success Payment Schedule Date of Payment Amount of Payment [***] days after the Success Payment Trigger [***] 1-Year Anniversary of the Success Payment Trigger [***] 2-Year Anniversary of the Success Payment Trigger [***] 3-Year Anniversary of the Success Payment Trigger [***] 4-Year Anniversary of the Success Payment Trigger [***] 5-Year Anniversary of the Success Payment Trigger [***] 6-Year Anniversary of the Success Payment Trigger [***] Total $395,000,000
Success Payments. Endo will make each of the following non-creditable, one-time success payments to Penwest within sixty (60) days following the end of the calendar quarter in which the corresponding event first occurs during the term of this Agreement: Event Success Payment Calendar year U.S. Product Net Sales exceed $400,000,000 $ 15,000,000 Calendar year U.S. Product Net Sales exceed $*** $ 25,000,000 Calendar year U.S. Product Net Sales exceed $*** $ 50,000,000 ”
